Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in lung adenocarcinoma patients that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies from seven patients obtained before, during and/or after treatment with AZD9291or rociletinib (CO-1686). Targeted sequencing and FISH analyses were performed and the relevance of candidate genes was functionally assessed in in vitro models. Results: We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compounds. Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance. Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS. Conclusions: Our data suggests that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provides a rationale for potential combination strategies.
- Received August 8, 2015.
- Revision received May 17, 2016.
- Accepted May 21, 2016.
- Copyright ©2016, American Association for Cancer Research.